Drug intelligence / Profile preview

Amro Forte

Development stage: Unknown
Lead developer: Taqwa Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Amro Forte** is an oral haematinic syrup marketed by Amros Pharmaceuticals and listed by Taqwa Pharmaceuticals. It is a fixed-dose combination containing ferric ammonium citrate, folic acid, pyridoxine hydrochloride, thiamine hydrochloride, and nicotinamide. The product is intended to replenish iron and vitamin cofactors involved in erythropoiesis and is used for iron-deficiency anaemia and related nutritional deficiency states.

Brand names: Amro ForteAmro Forte Syrup

Beyond the preview

Go deeper on Amro Forte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amro Forte.

Explore the full profile